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The value of vitamin D supplementation in the treatment 
or prevention of various conditions is often viewed with 
scepticism as a result of contradictory results of randomised 
trials. It is now becoming apparent that there is a pattern 
to these inconsistencies. A recent large trial has shown 
that high-dose intermittent bolus vitamin D therapy is 
ineffective at preventing rickets – the condition that is 
most unequivocally caused by vitamin D deficiency. There 
is a plausible biological explanation since high-dose bolus 
replacement induces long-term expression of the catabolic 
enzyme 24-hydroxylase and fibroblast growth factor 23, both 
of which have vitamin D inactivating effects. Meta-analyses of 
vitamin D supplementation in prevention of acute respiratory 
infection and trials in tuberculosis and other conditions also 
support efficacy of low dose daily maintenance rather than 
intermittent bolus dosing. This is particularly relevant during 
the current COVID-19 pandemic given the well-documented 
associations between COVID-19 risk and vitamin D deficiency. 
We would urge that clinicians take note of these findings 
and give strong support to widespread use of daily vitamin D 
supplementation.
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Introduction: contradictory results of vitamin D 
supplementation in clinical trials
Controversy surrounding the possible benefits from taking 
vitamin D supplements has become more prominent recently 
with the reports of various associations between vitamin D 
deficiency and risk of COVID-19.1 Authorities have given only 
muted support to avoidance of vitamin D deficiency during the 
current COVID-19 pandemic, concluding that there is insufficient 
evidence from randomised trials of supplementation to support 
any protective effect against COVID-19.2 Many randomised 
trials of vitamin D supplementation have been performed in a 
wide range of conditions with contradictory and often negative 
results that have led to considerable scepticism about its 
value.3,4 This may partly result from optimistic trial of vitamin D 
supplementation in widely diverse conditions, not always with 
a plausible mechanism of causation. It is becoming apparent, 
though, that the use of intermittent high-dose bolus, introduced 
to achieve high adherence, rather than regular daily maintenance 
could be an important explanation for the failure of vitamin D 
supplementation in some trials. 
Evidence that low-dose daily vitamin D 
supplementation is effective but intermittent  
high-dose bolus is not
Rickets
Rickets is the one condition above all others where there is 
conclusive and very longstanding evidence, dating back to the 
1920s, first in animals and then in children, of response to regular 
daily vitamin D, either via cod liver oil supplementation or later by 
food fortification.5 A recent well-conducted trial in 3,046 children 
has however shown that high-dose bolus vitamin D (100,000 IU 
every 3 months for 18 months) is ineffective at preventing rickets 
in children6 – indeed it is not the first trial to show this.7 A smaller 
study in 72 children with calcium-deficiency rickets showed that 
oral vitamin D2 50,000 IU monthly for 24 weeks had only a 
‘marginally significant effect’ (p=0.06) on recovery compared 
with calcium supplementation alone.8
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Tuberculosis
Tuberculosis is another condition for which there is longstanding 
evidence suggesting that vitamin D deficiency contributes to 
illness and susceptibility. As with rickets, this dates back a long 
way, a successful trial of daily cod liver oil in tuberculosis having 
been reported in 1848 from London’s Brompton Hospital.9 
However, although ultraviolet light and vitamin D therapy were 
well-established therapies, particularly in cutaneous tuberculosis, 
during the first half of the 20th century, controlled trials were not 
performed.10 A recent meta-analysis of vitamin D supplementation 
as an adjunct to chemotherapy for active pulmonary tuberculosis 
showed significantly accelerated sputum conversion but only in 
patients with multi-drug-resistant tuberculosis. In this analysis, 
only one of seven included studies trialled daily vitamin D 
supplementation.11 No significant difference was seen for daily 
or weekly supplementation combined versus bolus/2-weekly 
regimens. However, the single trial of daily supplementation 
(5,000 IU/day) versus placebo in 288 patients with active 
pulmonary tuberculosis did show significant benefit across the 
whole patient population, with 61.3% of patients culture-negative 
at 4 weeks compared with 42.2% placebo (p=0.032).12
In a 2015 review of vitamin D supplementation as prophylaxis 
against tuberculosis in high-risk individuals, it was noted that no 
randomised trials had yet taken place despite consistent evidence 
that vitamin D deficiency increases risk for developing active 
tuberculosis.13 There had however been one study looking at the 
effect of supplementation with 800 IU/day over 6 months in 120 
children from Mongolia, all with vitamin D deficiency (<50 nmol/L), 
which showed a trend towards fewer tuberculin skin test conversions 
(risk ratio [RR] 0.41, 95% confidence interval [CI] 0.16–1.09; 
p=0.06) and a significantly greater increase in stature (p<0.003).14 
Recently, a much larger trial in 8,851 children from Mongolia, 95.6% 
with vitamin D deficiency (<50 nmol/L), but this time using a weekly 
oral dose of 14,000 IU vitamin D3 compared with placebo, showed 
no impact on subsequent diagnosis of tuberculosis (adjusted RR 
0.87, 95% CI 0.49–1.55) or on risk of hospitalisation with acute 
respiratory infection (adjusted RR 0.86, 95%CI 0.52–1.40).15
Acute respiratory infections
The recent meta-analyses by Martineau and colleagues of the 
efficacy of vitamin D supplementation in prevention of acute 
respiratory infections have also reported that low dose daily 
maintenance supplementation is effective but intermittent 
high-dose bolus is not.16,17 In their most recent meta-analysis of 
42 randomised controlled trials, 47,262 subjects were analysed. 
A protective effect against risk for acute respiratory infection 
was seen for trials in which vitamin D supplements were given 
daily (odds ratio [OR] 0.70, 95% CI 0.61–0.93) but not for trials 
where vitamin D was given weekly (OR 0.97, 95% CI 0.88–1.06) or 
monthly to 3-monthly (OR 0.98, 95% CI 0.93–1.03).17
Thus for treatment or prevention of rickets, tuberculosis and acute 
respiratory infections, there is substantial evidence that it is daily 
vitamin D supplementation that is effective rather than intermittent 
high-dose boluses.
A plausible biological mechanism underlies the lack of 
efficacy of intermittent high-dose (bolus) vitamin D
Vitamin D (cholecalciferol) is synthesised in the skin by the action 
of ultraviolet B (UVB, wavelength 280–315 nm) on exposed skin, 
Fig 1. The complexity of vitamin D metabolism. D2 is from plant 
sources via ultraviolet action on ergosterol and D3 from animal 
sources via ultraviolet action on 7-dehydrocholesterol. Activation is via 
25-hydroxylation in the liver followed by 1α-hydroxylation (CYP27B1) in 
kidneys, immune cells and many epithelia, to 1,25(OH)2D. Increased FGF23 
suppresses 1α-hydroxylation. Free 25(OH)D appears to be preferentially 
taken up by monocytes,19 so the reduction in DBP in illness may have a 
protective effect via increased availability of free 25(OH)D. Either 25(OH)D  
or 1,25(OH)2D can be degraded via 24-hydroxylation (CYP24A1) to 
24,25(OH)D or 1,24,25(OH)3D respectively.
splitting a carbon-to-carbon bond (C9–C10) in the precursor 
7-dehydrocholesterol.18 Cholecalciferol is 25-hydroxylated in the 
liver and subsequently 1α-hydroxylated in the kidneys and in other 
tissues including immune cells and many epithelia to form the 
active metabolite 1,25 dihydroxycholecalciferol (1,25(OH)2D). The 
predominant circulating vitamin D is 25-hydroxycholecalciferol 
(25(OH)D), which is itself a substrate for local activation in tissues 
expressing the 1α-hydroxylase enzyme and is present in nanomolar 
concentrations, whereas circulating active 1,25(OH)2D is only 
present in picomolar concentrations. Like other lipophilic molecules, 
25(OH)D is bound to protein in serum, approximately 80% to 
the vitamin D binding protein (DBP) and 20% to albumin.19 Given 
that the vitamin D receptor (VDR) is predominantly a nuclear 
receptor, it is the intracellular concentration of 1,25(OH)2D that is 
most relevant and most/all cells that express the VDR, including 
osteoblasts and immune cells, also express 1α-hydroxylase activity, 
so circulating concentrations of 1,25(OH)2D may not always reflect 
intracellular concentrations. Currently, almost all studies of vitamin 
D rely on the measurement of serum 25(OH)D to determine 
vitamin D status but, given the complexities of variable protein 
binding in illness plus its complex metabolism, there is a need to 
consider other metabolites such as 1,25(OH)2D and 24,25(OH)2D, 
particularly in the setting of different dosing regimens. The half-life 
of 25(OH)D in the blood is around 2–3 weeks but the whole-body 
half-life is around 2–3 months, probably because cholecalciferol, 
which is lipid-soluble, is conserved in body fat.20 As a result it has 
been widely presumed that large intermittent boluses, which 
provide relatively stable 25(OH)D serum concentrations, could 
provide effective replacement.21
The metabolism of vitamin D is complex, however, and still 
incompletely understood (Fig 1). A large amount of cholecalciferol 
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can be generated rapidly by sunlight exposure – one full-body UV 
exposure causing slight skin pinkness is equivalent to 250–625 μg 
(10,000–25,000 IU) vitamin D3,18 whereas total daily requirement 
is only around 800–1,000 IU22 – so the level of activated vitamin 
D in the body could potentially vary enormously without robust 
regulatory mechanisms. 
It is impossible for vitamin D toxicity to occur through ultraviolet 
exposure (and extremely high repeated dosing is required for this 
to occur via supplementation). The principal regulatory check is via 
24-hydroxylation forming 24,25(OH)2D or 1,24,25(OH)3D, which 
are both largely inactive. The inactivating enzyme 24-hydroxylase 
CYP24A1 catalyses not only 24-hydroxylation but also 
23-hydroxylation, generating a series of polyhydroxylated products. 
Although these may have some biological activity, the importance 
of this process in inactivating vitamin D is demonstrated by the 
finding that inborn mutations of CYP24A1 cause idiopathic 
infantile hypercalcemia.23 CYP24A1 is expressed in cells containing 
the vitamin D receptor, including kidney, bone, intestine and 
dendritic cells, and increases markedly in response to rising levels 
of 25(OH)D.24 The intracellular balance between the activating 
1α hydroxylase CYP27B1 and the inactivating 24-hydroxylase 
CYP24A1 is thought to be critically important, particularly in extra-
skeletal tissues, for regulating activity of vitamin D.25 
Fig 2. Alterations in (a) serum concentration of 24,25(OH)2D, (b) serum concentration of 25(OH)D, (c) ratio of 24,25(OH)2D / 25(OH)D, and 
(d) serum concentration of cholecalciferol following a single dose of 150,000 IU vitamin D3 (open circles) and daily dose of 5000IU for 28 days 
(black triangles). The bars represent standard deviations. P values are for comparison of values in daily and single dosing groups at corresponding time 
points. It can be seen that single high-dose bolus vitamin D induces an increase in the inactivating 24-hydroxylase activity that lasts for around 4 weeks. 
Reproduced with permission from Ketha et al.26
It has only been recognised relatively recently that the increased 
24-hydroxylase activity, as a feedback control response to a large 
bolus of vitamin D, may itself have a long half-life – persisting 
for several weeks after the bolus dose26 (Fig 2). This implies that 
a single high-dose bolus of vitamin D could paradoxically lead 
to intracellular deficiency of activated vitamin D as a rebound 
phenomenon. This might be particularly important in immune 
cells such as the dendritic cells that are probably central to the 
hyperinflammatory state seen in severe COVID-19 and that seem 
particularly sensitive to this process.24
The role of fibroblast growth factor 23 (FGF23) in vitamin D 
regulation may be at least equally important in regulating activation 
of vitamin D. Its expression is increased in the presence of high 
serum 25(OH)D and 1,25(OH)D concentrations. A meta-analysis of 
23 studies has shown that vitamin D supplementation daily or at an 
equivalent of ≤2,000 IU/day had no significant effect on circulating 
FGF23 concentrations, whereas higher doses resulted in a significant 
increase (FGF23 +18 pg/ml, 95% CI 6–30), particularly when 
circulating 25(OH)D achieved was ≥100 nmol/L (p<0.001).27 The 
likely importance of this increase in FGF23 in the suppression of vitamin 
D activation is demonstrated by the condition tumour-associated 
osteomalacia, in which inappropriate FGF23 secretion by tumour 
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context of hypophosphatemia is considered the cut-off for diagnosis.28 
Importantly, the rise in FGF23 following vitamin D bolus is very long-
lasting. A single large intramuscular bolus of vitamin D2 (300,000 IU) 
given to 45 subjects induced a progressive 50% increase of circulating 
FGF23 over at least the following 3 months (p<0.01)29 (Fig 3). FGF23 
in-turn markedly suppresses 1α-hydroxylation of 25(OH)D resulting 
in reduced intracellular activation of vitamin D to 1,25(OH)2D as 
demonstrated in monocytes.30
In studies of dialysis patients, low serum 25(OH)D combined with 
high serum FGF23 was shown to associate strongly with infectious 
and cardiac events and all-cause mortality.31 
A simpler explanation might be that high-dose bolus 
supplementation yields blood concentrations of vitamin D that 
are harmful. This seems a less likely explanation for the lack of 
therapeutic effect of bolus supplementation, since potentially 
harmful blood concentrations are only approached very transiently 
if at all, eg in the first 24 hours after bolus administration of 
high-dose 25(OH)D32 and hypercalcaemia is rarely reported. 
There is also controversial population-based evidence to support a 
‘U-shaped curve’ with less benefit at higher mean serum 25(OH)D 
concentrations.33 This is disputed though34 and seems unlikely 
to explain the overall negative results of so many trials of bolus 
supplementation. There are of course other reasons for some of the 
negative trial results, including vitamin D being treated as a drug 
rather than a nutrient, often with inclusion of many participants 
with normal vitamin D status at baseline.35
Implications for COVID-19
There is therefore a clear biological explanation for the lack 
of efficacy of vitamin D supplementation when delivered as 
intermittent high-dose boluses. This lack of efficacy of bolus 
replacement is emphatically reinforced by the recent trial in 
rickets.6 If the literature on efficacy of vitamin D supplementation 
in treating or preventing various conditions including respiratory 
infections is reviewed with this in mind, the efficacy of regular daily 
maintenance vitamin D supplementation becomes much clearer 
and more convincing. This is borne out powerfully by the careful 
Fig 3. Changes in serum FGF23 after a single bolus of ergocalciferol 
(vitamin D2) 300,000 IU intramuscularly in 45 subjects with vitamin 
D deficiency/insufficiency. FGF23, which inhibits 1α -hydroxylase activity, 
is increased by 50% (P<0.01) 3 months after the bolus. Reproduced with 
permission from Turner et al.29
meta-analysis by Jolliffe, Martineau and colleagues that shows 
vitamin D supplementation is associated with significant reduction 
in risk for a range of acute respiratory infections but only when 
given as regular daily maintenance and not when given at weekly 
or 1–3-monthly intervals.17 Given that COVID-19 is also primarily a 
respiratory infection, this seems highly relevant.
We have pointed out elsewhere the links between vitamin D 
deficiency, latitude, seasonality, ultraviolet exposure, obesity, 
ethnicity and COVID-19 risk.1 There, and elsewhere,36 we have 
also discussed the complex impacts of illness on interpretation of 
circulating 25(OH)D concentrations in sick patients, the possibility 
of the ‘healthy user’ effect and the difficulties these present in 
drawing firm conclusions from association data. Nevertheless, 
the marked congruence between the risk factors for vitamin D 
deficiency and the risk factors for severe COVID-19 make the link 
very plausible. This is supported by the strongly positive results 
of high-dose 25(OH)D (calcifediol) therapy given three times in 
the first week then weekly in a small Spanish trial of hospitalised 
patients.37 It should be noted that high-dose bolus of 25(OH)D will 
also likely induce potentially deleterious induction of 24-hydroxylase 
and FGF23, as a consequence of commensurate elevation of 
serum 1,25(OH)2D.32 It is plausible though that repeated dosing, 
particularly in the first week of therapy as used in the Spanish 
trial, could override this. The use of 25(OH)D is interesting and 
unusual. Sick patients may have reduced hepatic 25-hydroxylation 
so correction of low serum 25(OH)D may be faster with 25(OH)
D supplementation than with standard cholecalciferol.38 The only 
other randomised trial, published as a pre-print, is a negative trial 
from Brazil of a bolus of 200,000 IU cholecalciferol given once 
only to patients admitted to hospital, randomised an average of 
10 days after symptom onset.39 Before the pandemic there have 
also been trials of vitamin D in patients admitted to intensive care 
but unfortunately these trials (nine to date) have also used high-
dose bolus cholecalciferol and have all proved negative.40 There is 
an ongoing international study (VITDALIZE) targeting vitamin-D-
deficient critically ill patients that also has a high frontloading bolus 
dose (540,000 IU cholecalciferol) but with regular 4,000 IU daily 
dosing afterwards for 90 days.41 
NICE has noted the considerable incidence of vitamin D deficiency 
in the UK, particularly in winter, and has recommended its 
supplementation ‘for bone and muscle health’ but has concluded 
that evidence is currently insufficient to recommend vitamin D 
supplementation for preventing or treating COVID-19. We have 
previously pointed out the difficulty of conducting a placebo-
controlled trial for a vitamin in the community.42 Waiting until the 
spring of 2021 at the earliest for the completion of any such trial 
would moreover lose the opportunity to mitigate COVID-19 risks 
earlier through correction of population vitamin D deficiency and 
the appropriate use of calcifediol in COVID-19 illness. 
It seems likely to us that much of the current scepticism about 
the benefits of vitamin D supplementation amongst clinicians, 
including perhaps those on advisory committees, comes from 
the contradictory results of trials investigating either bolus or 
maintenance supplementation. We urge health professionals 
to note the substantial evidence for efficacy of low-dose daily 
maintenance vitamin D, rather than intermittent bolus, against 
various relevant clinical endpoints and to move urgently to 
encourage the general population to avoid vitamin D deficiency, 
defined as <50 nmol/L.22 They should be urged to do this to support 
immune function rather than just bone and muscle health. In the 
Northern Hemisphere vitamin D deficiency is at peak incidence 
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from February to March and can be readily avoided by a daily 
supplement of 800–1,000 IU, preferably starting with a higher dose 
eg 4,000 IU/day for the first four weeks if deficiency is suspected,22 
for example in people with dark skin or living in residential care, 
shielding indoors or working night shifts. ■
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